<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811368</url>
  </required_header>
  <id_info>
    <org_study_id>367905</org_study_id>
    <secondary_id>UCDCC#233</secondary_id>
    <secondary_id>NCI-2012-02753</secondary_id>
    <nct_id>NCT01811368</nct_id>
  </id_info>
  <brief_title>Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Tuscano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem&#xD;
      cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma.&#xD;
      Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor&#xD;
      peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop&#xD;
      the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled&#xD;
      monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry&#xD;
      cancer-killing substances to them without harming normal cells. When the healthy stem cells&#xD;
      from a donor are infused into the patient they may help the patient's bone marrow make stem&#xD;
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells&#xD;
      from a donor can make an immune response against the body's normal cells. Giving rituximab,&#xD;
      antithymocyte globulin, and TLI before the transplant together with cyclosporine and&#xD;
      mycophenolate mofetil after the transplant may stop this from happening. Giving a&#xD;
      radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be&#xD;
      an effective treatment for non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To measure the response conversion (progressive disease [PD]/stable disease [SD] to&#xD;
      partial response [PR] and complete response [CR]).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the time to engraftment/chimerism. II. To assess the rate of acute and chronic&#xD;
      graft-versus-host disease (GVHD). III. To assess toxicity. IV. To determine the overall&#xD;
      survival. V. To investigate immune functional and phenotypic analysis. VI. To measure two&#xD;
      year event free survival (EFS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive rituximab intravenously (IV) on days -21 and 14,&#xD;
      ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte&#xD;
      globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and&#xD;
      -4 to -1.&#xD;
&#xD;
      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day&#xD;
      0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive cyclosporine orally (PO) twice daily (BID) or IV on days&#xD;
      -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response conversion rate (PD/SD to PR and CR)</measure>
    <time_frame>Up to 60 days post-transplant</time_frame>
    <description>Calculated along with 95% confidence intervals (CI). Logistic regression will be used to assess the impact of patient characteristics (e.g., low/high lactate dehydrogenase isoenzyme-3 [LDH] or immunologic correlates) on the response conversion rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment/chimerism</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute GVHD</measure>
    <time_frame>Up to day 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic GVHD</measure>
    <time_frame>Up to day 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to day 730</time_frame>
    <description>Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>Up to day 730</time_frame>
    <description>Toxicities as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory Non Hodgkin Lymphoma</condition>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.&#xD;
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>Zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total nodal irradiation</intervention_name>
    <description>Undergo TLI</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>TLI</other_name>
    <other_name>total lymphoid irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed relapsed cluster of differentiation (CD)20+&#xD;
             non-Hodgkin's lymphoma (NHL) (included in this category are follicular grade I, II,&#xD;
             III, marginal zone, mantle cell, diffuse large B cell, small lymphocytic lymphoma) and&#xD;
             CD20+ Hodgkin's disease for which standard curative therapy does not exist or is no&#xD;
             longer effective&#xD;
&#xD;
          -  Patients must have had at least one prior chemotherapeutic regimen; steroids alone and&#xD;
             local radiation do not count as regimens; radiotherapy must have been completed at&#xD;
             least 4 weeks prior to entry into the study; Rituxan alone does not count as a&#xD;
             regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have&#xD;
             completed radioimmunotherapy (RIT) &gt; 12 months prior to enrollment&#xD;
&#xD;
          -  Karnofsky performance status of â‰¥ 60%&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Total bilirubin within institutional normal limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 times institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60&#xD;
             ml/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  Blood counts no restrictions&#xD;
&#xD;
          -  Patients who had anything less than a CR (PR, SD or progressive disease) to their last&#xD;
             salvage regimen&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Patients fit for non-myeloablative transplantation or best treatment that have an&#xD;
             available matched (9/10 or better) related or unrelated donor&#xD;
&#xD;
          -  Patients who are considered rituximab refractory (defined as progression within 6&#xD;
             months of their last rituximab-containing regimen)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study, rituximab within three&#xD;
             months (unless there is evidence of progression), or those who have not recovered from&#xD;
             adverse events due to agents administered more than 4 weeks earlier are excluded; this&#xD;
             does not include the use of steroids which may continue until two days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Failure to obtain insurance/payment authorization for Zevalin, unless the subject&#xD;
             agrees to cover the cost&#xD;
&#xD;
          -  Patients with known active brain metastases, other neurological disorders/dysfunction&#xD;
             or a history of seizure disorder, or other neurological dysfunction should be excluded&#xD;
             from this clinical trial because of their poor prognosis&#xD;
&#xD;
          -  Patients who have an uncontrolled infection (presumed or documented) with progression&#xD;
             after appropriate therapy for greater than one month&#xD;
&#xD;
          -  Patients with symptomatic coronary artery disease, uncontrolled congestive heart&#xD;
             failure; left ventricular ejection fraction is not required to be measured, however if&#xD;
             it is measured, patient is excluded if ejection fraction is &lt; 30%&#xD;
&#xD;
          -  Patients requiring supplementary continuous oxygen; diffusion capacity of the lung of&#xD;
             carbon monoxide (DLCO) is not required to be measured, however if it is measured,&#xD;
             patient is excluded if DLCO &lt; 35%&#xD;
&#xD;
          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for&#xD;
             the cause of liver disease, its clinical severity in terms of liver function and&#xD;
             histology, and for the degree of portal hypertension&#xD;
&#xD;
          -  Patients with any of the following liver function abnormalities will be excluded:&#xD;
&#xD;
               -  Fulminant liver failure&#xD;
&#xD;
               -  Cirrhosis with evidence of portal hypertension or bridging fibrosis&#xD;
&#xD;
               -  Alcoholic hepatitis&#xD;
&#xD;
               -  Esophageal varices&#xD;
&#xD;
               -  A history of bleeding esophageal varices&#xD;
&#xD;
               -  Hepatic encephalopathy&#xD;
&#xD;
               -  Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the&#xD;
                  prothrombin time&#xD;
&#xD;
               -  Ascites related to portal hypertension&#xD;
&#xD;
               -  Chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dL&#xD;
&#xD;
               -  Symptomatic biliary disease&#xD;
&#xD;
          -  Pregnant women are excluded from this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Tuscano</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Joseph Tuscano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

